Literature DB >> 18726887

Morbidity, toxicity, and mortality classification systems in the local regional treatment of peritoneal surface malignancy.

Rami Younan1, Shigeki Kusamura, Dario Baratti, Alexis-Simon Cloutier, Marcello Deraco.   

Abstract

To reach a consensus for reporting complications related to cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Reporting the adverse events related to CRS + HIPEC is not standardized yet. Post-operative complications can be divided in two categories: the effects of surgical manipulation per se and the toxic effects of the heated intraoperative chemotherapy. Additive and/or synergistic effects also exist. Different centers have published their experience with regard to the complications associated with the procedure. Various classification systems have been used which makes a temptative comparison of the different techniques and results almost impossible. An effort was made here to review the existing major classification systems: The Bozzetti classification, the Clavien classification (and two proposed modifications from Feldman et al. and Elias et al.) and the Common terminology criteria for adverse events (CTCAE) version 3.0 of the National Institute of Health (NIH) criteria. A related document was sent to an international panel of experts. The CTCAE was adopted by the panel of experts as the unique classification system to be used for reporting complications related to CRS + HIPEC.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18726887     DOI: 10.1002/jso.21057

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  16 in total

1.  Pseudomyxoma peritonei treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: results from a single centre.

Authors:  Álvaro Arjona-Sánchez; Francisco C Muñoz-Casares; Sebastián Rufián-Peña; Rafael Díaz-Nieto; Ángela Casado-Adam; María J Rubio-Pérez; Rosa Ortega-Salas
Journal:  Clin Transl Oncol       Date:  2011-04       Impact factor: 3.405

2.  Cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion: The University of Arizona early experience.

Authors:  Ioannis T Konstantinidis; Christine Young; Vassiliki L Tsikitis; Ellyn Lee; Tun Jie; Evan S Ong
Journal:  World J Gastrointest Surg       Date:  2012-06-27

3.  Splenectomy revisited in 2011: Impact on hematologic toxicities while performing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

Authors:  Nancy Deslauriers; Harold Olney; Rami Younan
Journal:  J Gastrointest Oncol       Date:  2011-06

4.  Early and long-term postoperative management following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

Authors:  Dario Baratti; Shigeki Kusamura; Barbara Laterza; Maria Rosaria Balestra; Marcello Deraco
Journal:  World J Gastrointest Oncol       Date:  2010-01-15

5.  Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal malignant disease.

Authors:  Wenceslao Vásquez Jiménez; Luis González Bayón; José Luis García-Sabrido; Santiago González Moreno
Journal:  Clin Transl Oncol       Date:  2010-12       Impact factor: 3.405

6.  Hemodynamic Monitoring During Heated Intraoperative Intraperitoneal Chemotherapy Using the FloTrac/Vigileo System.

Authors:  Christos Mavroudis; Leonidas Alevizos; Konstantinos M Stamou; Theodosia Vogiatzaki; Savvas Eleftheriadis; Odysseas Korakianitis; Antonios A Tentes; Christos Iatrou
Journal:  Int Surg       Date:  2015-01-15

7.  Outcome of patients with aggressive pseudomyxoma peritonei treated by cytoreductive surgery and intraperitoneal chemotherapy.

Authors:  Alvaro Arjona-Sanchez; Francisco Cristobal Muñoz-Casares; Angela Casado-Adam; Juan Manuel Sánchez-Hidalgo; Maria Dolores Ayllon Teran; Rafael Orti-Rodriguez; Ana Cristina Padial-Aguado; Javier Medina-Fernández; Rosa Ortega-Salas; Gema Pulido-Cortijo; Auxiliadora Gómez-España; Sebastián Rufián-Peña
Journal:  World J Surg       Date:  2013-06       Impact factor: 3.352

8.  Implementation of a standardized HIPEC protocol improves outcome for peritoneal malignancy.

Authors:  Anke M J Kuijpers; Arend G J Aalbers; Simon W Nienhuijs; Ignace H J T de Hingh; Marinus J Wiezer; Bert van Ramshorst; Robert J van Ginkel; Klaas Havenga; Wilma D Heemsbergen; Michael Hauptmann; Victor J Verwaal
Journal:  World J Surg       Date:  2015-02       Impact factor: 3.352

9.  Where Oncologic and Surgical Complication Scoring Systems Collide: Time for a New Consensus for CRS/HIPEC.

Authors:  Kuno Lehmann; Dilmurodjon Eshmuminov; Ksenija Slankamenac; Benedict Kranzbühler; Pierre-Alain Clavien; René Vonlanthen; Philippe Gertsch
Journal:  World J Surg       Date:  2016-05       Impact factor: 3.352

10.  Uncommon indications for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

Authors:  Francis Zheng Yi Yee; Grace Hwei Ching Tan; Claramae Shulyn Chia; Khee Chee Soo; Melissa Ching Ching Teo
Journal:  Pleura Peritoneum       Date:  2017-08-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.